Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu
Trial record 1 of 1 for:    NCT03627611
Previous Study | Return to List | Next Study

Identification of Non-responders to Levothyroxine Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03627611
Recruitment Status : Completed
First Posted : August 13, 2018
Last Update Posted : March 17, 2021
Spesialistsenteret Pilestredet Park
Information provided by (Responsible Party):
Erik Fink Eriksen, Oslo University Hospital

Brief Summary:
The purpose of this study is to assess differential effects of T4 and T3 on cell and tissue level

Condition or disease Intervention/treatment Phase
Hypothyroidism Biomarkers Endocrine System Diseases Drug: Levothyroxin Drug: Liothyronine Phase 2

Detailed Description:
15-20% of the patients with hypothyroidism remain symptomatic, despite adequate thyroxine substitution. Endocrinologists are split in their opinion on combination therapy with T4 and T3 on patients with poorly regulated hypothyroidism. There are no objective means, by which to identify individuals who would benefit from combination therapy. The purpose of this study is to assess differential effects of T4 and T3 on body temperature, metabolism, muscle strength and brain function. The main aim is to try to identify biomarkers reflecting different effects of T4 and T3 on cell and tissue level.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 69 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Crossover Study, Examining Differential Effects of Levothyroxine and Liothyronine
Actual Study Start Date : August 14, 2018
Actual Primary Completion Date : June 22, 2020
Actual Study Completion Date : June 22, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: T4 Drug: Levothyroxin
3 months

Experimental: T3 Drug: Liothyronine
3 months

Primary Outcome Measures :
  1. Brown adipose tissue activation [ Time Frame: 6 months ]
    Thermal imaging of supraclavicular fossa

Secondary Outcome Measures :
  1. Body temperature [ Time Frame: 6 months ]
    Rectal thermometer

  2. Energy expenditure [ Time Frame: 6 months ]
    Indirect calorimetry

  3. Muscle strength [ Time Frame: 6 months ]
    Hand grip test

  4. ThyPRO Questionnaire [ Time Frame: 6 months ]
    Thyroid patient reported outcome, 13 multi-item scale, range 0-100 with higher scores indicating poorer health status

  5. Mean levels of thyroid hormones [ Time Frame: 6 months ]
    TSH, free T4 and free T3

  6. SF-36 Questionnaire [ Time Frame: 6 months ]
    Short form health survey, 8 multi-item scale, range 0-100 with higher scores indicating better health status

  7. Fatigue Questionnaire [ Time Frame: 6 months ]
    11 item, range 0-33 with higher scores implying higher levels of fatigue

  8. New biomarkers [ Time Frame: 6 months ]
    Bone marrow fat, serum and urine

  9. Micro-RNA, miR-92a [ Time Frame: 6 months ]
    Serum exosomes

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Poorly regulated hypothyroidism
  • Female aged between 18 and 65 years
  • Written informed consent obtained from the patient according to national regulations

Exclusion Criteria:

  • Cardiovascular disease
  • Chronic liver disease
  • Chronic kidney disease
  • Any other endocrinological disease
  • Use of beta blockers
  • Pregnant or lactating females
  • Hormonal substitution other than T3 and T4
  • Known psychiatric disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03627611

Layout table for location information
Oslo University Hospital
Oslo, Norway
Sponsors and Collaborators
Oslo University Hospital
Spesialistsenteret Pilestredet Park
Layout table for investigator information
Principal Investigator: Erik Fink Eriksen, Professor Department of Endocrinology, Morbid Obesity and Preventive Medicine
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Erik Fink Eriksen, Professor, Oslo University Hospital Identifier: NCT03627611    
Other Study ID Numbers: 2017/1883 (REK)
2017-003673-34 ( EudraCT Number )
First Posted: August 13, 2018    Key Record Dates
Last Update Posted: March 17, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Erik Fink Eriksen, Oslo University Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Endocrine System Diseases
Thyroid Diseases